Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8897402 | 0.86 | MAPT (0.49) | MAPTTDP1ALDH1A1MYCPPARG | |
| SCHEMBL19705421 | 0.86 | MAPT (0.51) | MAPTTDP1ALDH1A1MYCPPARG | |
| SCHEMBL1960268 | 0.85 | MAPT (0.42) | MAPTTDP1ALDH1A1MYCCDC25B | |
| SCHEMBL3782773 | 0.83 | MAPT (0.62) | MAPTTDP1ALDH1A1MYCPPARG | |
| SCHEMBL13285652 | 0.81 | MAPT (0.47) | MAPTTDP1ALDH1A1MYCPPARG | |
| SCHEMBL10901788 | 0.81 | GABRP (0.43) | TDP1ALDH1A1MYCPPARGTSHR | |
| SCHEMBL3966914 | 0.81 | MAPT (0.44) | MAPTTDP1ALDH1A1MYCPPARG | |
| SCHEMBL12310835 | 0.81 | S1PR3 (0.46) | — | |
| SCHEMBL732725 | 0.80 | MAPT (0.61) | MAPTTDP1ALDH1A1MYCCDC25B | |
| SCHEMBL13607855 | 0.79 | MAPT (0.57) | MAPTTDP1ALDH1A1MYCPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349983-B1 | DIFLUORPHENYL DIACYLHYDRAZIDE DERIVATES | MERCK PATENT GMBH (DE) | 2016-09-14 | — | — | EP | disclosed |
| EP-2349983-B1 | DIFLUORPHENYL DIACYLHYDRAZIDE DERIVATES | MERCK PATENT GMBH (DE) | 2016-09-14 | — | — | EP | disclosed |
| EP-2313380-B1 | OXADIAZOLE DERIVATIVES FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2013-12-11 | — | — | EP | disclosed |
| US-8546613-B2 | SGK1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546613-B2 | SGK1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8492440-B2 | Difluorophenyldiacylhydrazide derivatives | MERCK PATENT GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-8492440-B2 | Difluorophenyldiacylhydrazide derivatives | MERCK PATENT GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-8492440-B2 | Difluorophenyldiacylhydrazide derivatives | MERCK PATENT GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-8377975-B2 | Oxadiazole derivatives for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-02-19 | — | — | US | disclosed |
| US-8377975-B2 | Oxadiazole derivatives for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-02-19 | — | — | US | disclosed |
| US-20110139654-A1 | OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
| US-20110139654-A1 | OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
| US-20110139654-A1 | OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
| US-20110060050-A1 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS | MERCK PATENT GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20110060050-A1 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS | MERCK PATENT GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| EP-2242738-A1 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS | Merck Patent GmbH (DE) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010060522-A2 | DIFLUORPHENYL DIACYLHYDRAZIDE DERIVATES | MERCK PATENT GMBH (DE) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010060522-A2 | DIFLUORPHENYL DIACYLHYDRAZIDE DERIVATES | MERCK PATENT GMBH (DE) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010020305-A1 | OXADIAZOLE DERIVATIVES FOR TREATING DIABETES | MERCK PATENT GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2009103484-A1 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS | MERCK PATENT GMBH (DE) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110139654-A1 | OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES | PFKL, RXFP3, OXA1L | MAPT 4325/4885TDP1 1697/4885ALDH1A1 2507/4885 |
| US-20110060050-A1 | SGK1 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF VIRAL DISEASES AND/OR CARCINOMAS | NCOA1, NR3C2, NCOA2 | MAPT 2569/4885TDP1 3849/4885ALDH1A1 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.